Table 1.
CMTM6 expression and clinicopathological features
| Variables | Number of cases (%) | CMTM6 expression | P value* | |
| Low (n=94) | High (n=139) | |||
| Gender | ||||
| Male | 131 (56.2) | 58 (24.9) | 73 (31.3) | 0.180 |
| Female | 102 (43.8) | 36 (15.5) | 66 (28.3) | |
| Age (years) | ||||
| <60 | 120 (51.5) | 49 (21.0) | 71 (30.5) | 0.894 |
| ≥60 | 113 (48.5) | 45 (19.3) | 68 (29.2) | |
| Pathology | ||||
| AC | 133 (57.1) | 48 (20.6) | 85 (36.5) | 0.139 |
| MAC | 100 (42.9) | 46 (19.7) | 54 (23.2) | |
| Anatomy | ||||
| Colon | 158 (67.8) | 75 (32.2) | 83 (35.6) | 0.002 |
| Rectum | 75 (32.2) | 19 (8.2) | 56 (24.0) | |
| Location | ||||
| Left | 68 (29.2) | 30 (12.9) | 38 (16.3) | 0.466 |
| Right | 165 (70.8) | 64 (27.5) | 101 (43.3) | |
| pT classification | ||||
| T1–3 | 133 (57.1) | 62 (26.6) | 71 (30.5) | 0.031 |
| T4 | 100 (42.9) | 32 (13.7) | 68 (29.2) | |
| pN classification | ||||
| N0 | 134 (57.5) | 55 (23.6) | 79 (33.9) | 0.893 |
| N1–2 | 99 (42.5) | 39 (16.7) | 60 (25.8) | |
| pM classification | ||||
| M0 | 212 (91.0) | 83 (35.6) | 129 (55.4) | 0.252 |
| M1 | 21 (9.0) | 11 (4.7) | 10 (4.3) | |
| Clinical stage | ||||
| I–II | 130 (55.8) | 51 (21.9) | 79 (33.9) | 0.788 |
| II–IV | 103 (44.2) | 43 (18.5) | 60 (25.8) | |
| CEA (ng/μL) | ||||
| <5 | 107 (45.9) | 48 (20.6) | 59 (25.3) | 0.228 |
| ≥5 | 126 (54.1) | 46 (19.7) | 80 (34.3) | |
| CA19-9 (kU/L) | ||||
| <35 | 169 (72.5) | 63 (27.0) | 106 (45.5) | 0.136 |
| ≥35 | 64 (27.5) | 31 (13.3) | 33 (14.2) | |
| PD-L1(TS) | ||||
| Negative | 141 (60.5) | 63 (27.0) | 78 (33.5) | 0.103 |
| Positive | 92 (39.5) | 31 (13.3) | 61 (26.2) | |
| PD-L1(CC) | ||||
| Negative | 178 (76.4) | 74 (31.8) | 104 (44.6) | 0.532 |
| Positive | 55 (23.6) | 20 (8.6) | 35 (15.0) | |
| PD-L1 (whole) | ||||
| Negative | 163 (70.0) | 71 (30.5) | 92 (39.5) | 0.146 |
| Positive | 70 (30.0) | 23 (9.9) | 47 (20.2) | |
*P values were calculated using a two-sided Wald χ2 test. P value <0.05 in bold is statistically significant.
AC, adenocarcinoma; CA19-9, carbohydrate antigen 19-9; CC, cancer cells; CEA, carcinoembryonic antigen; CMTM6, CKLF-like MARVEL transmembrane domain-containing 6; MAC, mucinous adenocarcinoma; PD-L1, programmed death-ligand 1; TS, tumor stroma.